INTRODUCTION {#Sec1}
============

In the United States, approximately one in three adults aged 65 years and older has chronic kidney disease (CKD), defined as an eGFR \< 60 ml/min/1.73 m^2^.[@CR1] The majority of patients with CKD do not progress to advanced stages of CKD because death precedes the progression to end-stage renal disease (ESRD),[@CR2]--[@CR4] even among patients with stage 4 CKD.[@CR2] The risk of death as compared to the risk of progression to ESRD may be even higher in older patients with established CKD. To date, studies have not specifically examined the comparative event rates of kidney disease progression and death and determined cause-specific death in older adults with established CKD. Given the aging population,[@CR5] the increasing prevalence of CKD,[@CR6] and the association of CKD with mortality,[@CR7]--[@CR9] understanding the clinical course and outcomes of older patients with CKD is particularly important. For these reasons, we examined the rates of ESRD, cardiovascular death (CV death), and non-cardiovascular death (non-CV death) among older, community-dwelling adults with moderate CKD, and we determined the risk factors for progression from CKD to ESRD and to death within a competing mortality risk framework.

METHODS {#Sec2}
=======

**Participants** The Cardiovascular Heath Study (CHS) is a prospective cohort study of community-dwelling persons 65 years of age and older designed to examine the epidemiology of cardiovascular disease in older adults.[@CR10] Between 1989 and 1990, the CHS recruited 5,201 Medicare-eligible participants from Forsyth County, NC; Sacramento County, CA; Washington County, MD; and Pittsburgh, PA.[@CR11] Between 1992 and 1993, the study recruited an additional 687 African-American participants. CHS exclusion criteria included: institutionalization, inability to provide informed consent, intention to move outside the enrollment area within 3 years, use of a wheelchair within the home, hospice care, or current chemotherapy or radiation for cancer. At the time of study entry, extensive clinical data were collected, including demographics, comorbid conditions, biochemical data, and prevalent cardiovascular risk factors. Participants were followed prospectively for cardiovascular events (coronary artery disease, angina, congestive heart failure, stroke, claudication), hospitalizations, and death by contact every 6 months.[@CR12],[@CR13]To focus on the competing risks of death versus progression of chronic kidney disease, we selected only those CHS participants with a Modification of Diet in Renal Disease estimated glomerular filtration rate (MDRD eGFR) \< 60 ml/min per 1.73 m^2^ at baseline. We further excluded participants if they had no baseline serum creatinine measurement, prevalent ESRD requiring dialysis therapy, or the cause of death could not be determined.

**Outcomes** The primary outcomes of interest were ESRD (defined as renal failure requiring renal replacement therapy) and death; CV and non-CV death were secondary outcomes of interest. To ascertain ESRD, the CHS cohort was linked to the United States Renal Data System (USRDS) in 2005 (which included data through March 31, 2003). In addition, a chart review was performed to determine which CHS participants met criteria for ESRD yet elected not to initiate dialysis, died prior to receiving dialysis, or died prior to being enrolled in the USRDS (e.g., initiated dialysis in the hospital and subsequently withdrew dialysis). To identify these potential CHS participants with ESRD who were not included in the USRDS, charts of CHS participants were reviewed if the participant had a procedure code for dialysis, discharge diagnoses suggesting ESRD (e.g., renal failure, ESRD, dialysis, or renal transplant), or the cause of death was renal failure or failure to thrive. The charts were reviewed by one investigator (LF), and potential cases were reviewed by the CHS renal working group for concurrence.CV death was defined as death due to cardiovascular, cerebrovascular, atherosclerotic, or other vascular causes, and was adjudicated by the CHS Events Subcommittee by a protocol previously described in detail;[@CR12] any death other than those mentioned above was considered to be a non-CV death (e.g., cancer, dementia, pulmonary disease, or infection). In the CHS study, death was determined by examining the Social Security Death Index, Medicare claims data, local obituaries, and proxy report. The cause of death was adjudicated by committee and was based on review of medical records, death certificates, autopsy reports, and descriptions by the proxy.[@CR12],[@CR14] Participants were followed until the time of a first event or until March 31, 2003, whichever came first.

Clinical Assessment and Measurement {#Sec3}
-----------------------------------

All methods employed to asses the baseline characteristics of the CHS cohort have been described elsewhere.[@CR10],[@CR13],[@CR15] Demographic factors (age, gender, race), health behaviors (smoking), co-existing illnesses (diabetes and hypertension), physical exam findings (body mass index, systolic and diastolic blood pressure), and laboratory values (total cholesterol, creatinine and glucose) were ascertained at study entry. Diabetes was defined by the use of a medication for diabetes or fasting glucose level ≥ 126 mg/dl. Hypertension was defined by systolic pressure ≥ 140 mmHg, diastolic pressure ≥ 90 mm Hg, or the use of antihypertensive medication(s). Prevalent coronary heart disease (CHD) and prevalent congestive heart failure (CHF) were defined using participant self-report, medical record review, findings from the baseline physical examination, and physician questionnaires.[@CR13] Smoking was classified as never, former, or current. Serum creatinine levels were measured using the Kodak Ektachem 700 Analyzer (Eastman Kodak, Rochester, New York), a colorimetric method. Serum creatinine was calibrated to the Cleveland Clinic Laboratory using indirect calibration to the NHANES III data.[@CR16] Creatinine-based estimated GFR was calculated using the four-variable Modification of Diet in Renal Disease (MDRD) equation,.[@CR17]

Statistical Analyses {#Sec4}
--------------------

Baseline characteristics by categories of MDRD eGFR (eGFR 45 to \< 60 or \<45 ml/min per 1.73 m^2^) were described as means, medians, or proportions. Unadjusted incidence rates for progression to ESRD and all-cause mortality (further categorized as CV or non-CV related) were calculated per 100 person-years and also described with respect to eGFR categories. A standard Cox proportional hazards model analysis was not felt to be adequate in the presence of competing risks because the cause-specific Cox model treats competing risks of the event of interest as censored observations, and the cause-specific hazard function does not have a direct interpretation in terms of survival probability. Therefore, a competing risk model was used to examine risk factors for ESRD as compared with all-cause mortality. The variables included in the competing risk model were age, gender, race, BMI (\<18.5, 18.5--24.9, 25--29.9, or ≥30), hypertension, diabetes, cardiovascular disease, heart failure, tobacco use (never, former, or current), eGFR, and total cholesterol (\<200, 200--239, or ≥240 mg/dl). These variables were selected for inclusion in the analysis because of their potential association with the risk of ESRD and/or death and their availability in usual clinical practice (thereby allowing for inference by clinicians). First, we computed the cumulative incidence function (CIF) of ESRD over time. At time *t*, the CIF defined the probability of having ESRD by time *t* while other participants had experienced a death (CV or non-CV). We used the method proposed by Fine and Gray, which is based on the proportional hazards model and models directly the effect of covariates on the CIF for competing risk data.[@CR18] Our model distinguished between participants who were still alive and those who had already failed from competing causes and allowed for direct inference regarding the effects of covariates on the CIF. The cumulative incidence of ESRD in the presence of CV and non-CV mortality as competing risks was calculated similarly to the Kaplan-Meier method, except in the competing risk method participants who died were counted as events when calculating the event-free survival and only participants who were truly alive were considered at risk for ESRD. Similarly, the cumulative incidences of CV and non-CV mortality in the presence of ESRD as a competing risk were calculated. All analyses were performed using R 2.9.1 software (R Foundation for Statistical Computing <http://www.R-project.org>) and SPSS statistical software (release 15.0.1.1, Chicago, IL).

Investigational Review Board approval for the data collection procedures of CHS was obtained at each of the four clinical sites and at the Data Coordinating Center (University of Washington).

RESULTS {#Sec5}
=======

CHS enrolled 5,888 participants,[@CR11] and after exclusions, a total of 1,268 subjects were included in the present study (Fig. [1](#Fig1){ref-type="fig"}). The mean age of the cohort was 75 years, 46% of the cohort was male, and the mean and median eGFR at study entry were 51 and 53 ml/min per 1.73 m^2^, respectively. At study entry 77.7% of the cohort had stage 3a CKD (eGFR 45--59 ml/min per 1.73 m^2^), 18.3% had stage 3b CKD (eGFR 30--44 ml/min per 1.73 m^2^), 3.4% had stage 4 CKD (eGFR 15--29 ml/min per 1.73 m^2^), and 0.6% had stage 5 CKD not requiring dialysis (eGFR \< 15 ml/min/1.73 m^2^). Among the participants, 33% had prevalent cardiovascular disease, 17% had prevalent diabetes, and 69% had prevalent hypertension (Table [1](#Tab1){ref-type="table"}). The mean and median follow-up times were 8.9 and 9.7 years, respectively. Figure 1Recruitment of Cardiovascular Health Study participants and selection of chronic kidney disease cohort.Table 1Baseline Participant CharacteristicseGFR \< 60 ml/min/1.73 m^2^ n = 1,268eGFR 45 to \<60 ml/min/1.73 m^2^ n = 985eGFR \< 45 ml/min/1.73 m^2^ n = 283MDRD eGFR^*a*^ (ml/min/1.73 m^2^)51 ± 955 ± 436 ± 8Age (years)75 ± 674 ± 677 ± 7Male580 (46%)440 (45%)140 (50%)African-American140 (11%)97 (10%)43 (15%)Body mass index (kg/m^2^)26.7 ± 4.626.7 ± 4.626.5 ± 4.7Diabetes217 (17%)157 (16%)60 (21%)Hypertension877 (69%)656 (67%)221 (78%)Prevalent cardiovascular disease414 (33%)297 (30%)117 (41%)Prevalent heart failure104 (8%)64 (7%)40 (14%)Systolic blood pressure (mmHg)139 ± 23138 ± 23143 ± 25Diastolic blood pressure (mmHg)71 ± 1271 ± 1271 ± 13Antihypertensive medications792 (63%)579 (59%)213 (75%)ACEI^*b*^149 (12%)102 (10%)47 (17%)Smoking statusFormer537 (42%)425 (43%)112 (40%)Current128 (10%)94 (10%)34 (12%)Total cholesterol (mg/dl)212 ± 42212 ± 41212 ± 46Low density lipoprotein (mg/dl)131 ± 38131 ± 37132 ± 42High density lipoprotein (mg/dl)51 ± 1552 ± 1549 ± 16Data are presented as mean ± SD or number (%) of subjects; ^a^Modification of Diet in Renal Disease estimated glomerular filtration rate; ^b^angiotensin-converting enzyme inhibitor

During follow-up there were a total of 768 deaths (61% of cohort); of these, 338 were due to cardiovascular causes (44%), and 430 (56%) were due to non-cardiovascular causes. Sixty participants (4.7%) progressed to ESRD. Figure [2](#Fig2){ref-type="fig"} shows the cumulative incidence of events with consideration of the competing risk. Of the 60 participants with ESRD, 50 were identified through linkage to USRDS, and a further 10 were identified through chart review. Overall, the rates per 100 person-years were 0.5 for ESRD and 6.8 for all-cause mortality (3.0 for CV and 3.8 for non-CV mortality). The rates of events were notably higher in those participants with an eGFR \< 45 ml/min per 1.73 m^2^ and in participants over 85 years of age (Table [2](#Tab2){ref-type="table"}). Figure 2The cumulative incidence of end-stage renal disease (ESRD), cardiovascular death, and non-cardiovascular death during follow-up.Table 2Rates of End-Stage Renal Disease, All-Cause, Cardiovascular and Non-Cardiovascular MortalityNEnd-stage renal diseaseAll-cause mortalityCardiovascular mortalityNon-cardiovascular mortalityEventsRate per 100 person-years (95% CI)EventsRate per 100 person-years (95% CI)EventsRate per 100 person-years (95% CI)EventsRate per 100 person-years (95% CI)MDRD eGFR^*a*^\<601,268600.5 (0.4, 0.7)7686.8 (6.4, 7.3)3383.0 (2.7, 3.3)4303.8 (3.5, 4.2)45 to \<60985260.3 (0.2, 0.4)5706.1 (5.6, 6.6)2452.6 (2.3, 3.0)3253.5 (3.1, 3.9)\<45283341.8 (1.2, 2.4)19810.3 (8.8, 11.7)934.8 (3.8, 5.8)1055.4 (4.4, 6.5)Age (years)65--75745410.5 (0.4, 0.7)3554.8 (4.3, 5.3)1502.0 (1.7, 2.3)2052.8 (2.4, 3.1)76--85449150.4 (0.2, 0.7)34610.2 (9.1, 11.3)1504.4 (3.7, 5.1)1965.8 (5.0, 6.6)\>857441.1 (0.0, 2.1)6718.1 (13.7, 22.4)3810.2 (7.0, 13.5)297.8 (5.0, 10.7)^a^Modification of Diet in Renal Disease estimated glomerular filtration rate in ml/min per 1.73 m^2^

In the multivariate Cox proportional hazards model with a competing risk framework, factors associated with an increased risk of progression to ESRD included male gender, African-American race, a BMI ≥ 25 (as compared with a BMI of 18.5-24.9), and lower eGFR. In comparison, older age, male gender, a BMI \< 18.5 (compared with a BMI of 18.5--24.9), hypertension, diabetes, cardiovascular disease, heart failure, and former and current tobacco use were each associated with an increased risk of all-cause mortality (Table [3](#Tab3){ref-type="table"}). Table 3Risk Factors for Progression to ESRD and All-Cause Mortality Within the Competing Risk FrameworkESRDAll-cause mortalityHR (95% CI)p-valueHR (95% CI)p-valueAge, per 5 year increase0.64 (0.50, 0.83)\<0.0011.61 (1.51, 1.71)\<0.001Male2.73 (1.54, 4.82)\<0.0011.31 (1.12, 1.54)\<0.001African American2.13 (1.17, 3.90)0.0140.78 (0.58, 1.06)0.108BMI^*a*^\<18.5(No cases)-2.37 (1.37, 4.10)0.00218.5--24.91.00 (Ref)1.00 (Ref)25--29.92.38 (1.14, 5.00)0.0210.98 (0.83, 1.16)0.821≥302.45 (1.11, 5.41)0.0270.88 (0.70, 1.11)0.282Hypertension1.25 (0.88, 1.78)0.2111.25 (1.12, 1.39)\<0.001Diabetes mellitus1.74 (0.95, 3.19)0.0721.57 (1.29, 1.92)\<0.001Cardiovascular disease0.65 (0.36, 1.21)0.1731.38 (1.18, 1.62)\<0.001Heart failure1.05 (0.46, 2.40)0.7981.77 (1.33, 2.35)\<0.001Smoking statusNever1.00 (Ref)1.00 (Ref)Former0.48 (0.26, 0.91)0.0241.36 (1.16, 1.61)\<0.001Current0.53 (0.21, 1.33)0.1752.25 (1.75, 2.90)\<0.001eGFR^*b*^ , per 10 ml/min/1.73 m^2^ decrease3.25 (2.53, 4.18)\<0.0011.04 (0.95, 1.13)0.460Total cholesterol\<2001.00 (Ref)1.00 (Ref)200--2390.86 (0.45, 1.64)0.6500.90 (0.76, 1.06)0.199≥2401.59 (0.84, 3.01)0.1560.94 (0.76, 1.16)0.558^a^Body mass index, ^b^Modification of Diet in Renal Disease estimated glomerular filtration rate

DISCUSSION {#Sec6}
==========

In our study of community-dwelling older persons with CKD, we found participants were 13-fold more likely to die from any cause than to progress to ESRD and 6-fold more likely to die from cardiovascular-related causes. Among participants 76 to 85 years of age, the risk of death was more than 25-fold higher than the risk of ESRD. Even among participants with more advanced CKD (eGFR \< 45 ml/min per 1.73 m^2^), death from any cause was six-fold more likely than progression to ESRD. Importantly, 61% of patients died, and only 5% of patients developed ESRD during a median follow-up of more than 9 years.

Prior studies in disparate settings have compared risks for ESRD versus death in patients with CKD. The overall findings of our study are most similar to those from administrative data-based cohorts of CKD patients receiving care either in a Health Maintenance Organization (HMO)[@CR2] or in Veterans Affairs Medical Centers;[@CR19] both of these prior studies found older patients with moderate CKD were substantially more likely to die than to reach ESRD. However, in these studies, cause-specific death was not determined, and the mean follow-up time ranged from only 3 to 4 years for patients with moderate to severe CKD. On the opposite extreme from CHS are the findings of Menon et al. from the MDRD Study participants.[@CR20] Among 1,666 randomized and nonrandomized participants with predominantly stages 2 through 4 non-diabetic CKD, participants were seven-fold more likely to develop ESRD than to die prior to reaching ESRD. Even among participants more than 65 years of age, the rate of ESRD was double the rate of death. Differences between the MDRD cohort and CHS likely explain the differences in findings, including the younger age (mean age 50 years), the relatively low prevalence of CVD (8%), the large proportion of participants with polycystic kidney disease (23%), and the inclusion of patients selected for a RCT in the MDRD Study. Our CHS findings also differ from those of CKD patients referred for nephrologist care, who have been observed to have either higher or equal rates of ESRD as compared with rates of death.[@CR21],[@CR22] However, referred patients may differ from non-referred patients in important ways including their perceived health status and dialysis candidacy.[@CR23] Our findings allow clinicians to understand more generally the competing risks of death and ESRD in their older patients with CKD and expand on the previous findings as we determined the specific rates of competing events and compared risk factors for both ESRD and all-cause mortality within a competing risk framework. In our study, the rate of CV-related death approached the rate of all other causes of death combined. Although we did not specifically examine the different types of non-CV-related death, a previous CHS study by Fried et al.[@CR7] found that among participants with CKD, the leading cause of non-CV death was cancer, and the rate of cancer-related deaths was lower than the rate of CV deaths (16.7 versus 28 per 1000 person-years).

In the competing risk framework, lower eGFR, male gender, African-American race, and higher BMI were associated with an increased risk of progression to ESRD. Bi-directional effects of age, tobacco use, and BMI were observed. Older age and former tobacco use were associated with a reduced risk of progression to ESRD and an increased risk of death, whereas current tobacco use was associated with a substantial increase in the risk of death, suggesting that age and tobacco use were stronger predictors of death than ESRD (i.e., a risk factor for renal function decline, such as tobacco, was in fact a much stronger predictor of death in the competing risk framework). Higher BMI was associated with an increased risk of progression to ESRD but not death, whereas a low BMI was associated with a significant increase in the risk of death (similar to findings from previous CHS studies[@CR24],[@CR25]). Although diabetes and hypertension were not statistically significantly associated with an increased risk of ESRD, the point estimates were consistent with an increased risk of ESRD and were likely not statistically significant because of the low number of patients reaching ESRD.

Interestingly, renal function was an important predictor of ESRD but not all-cause mortality. Older age, cardiovascular disease, heart failure, and current tobacco use, all of which were more prevalent among participants with lower eGFR, appeared to have a greater influence on the likelihood of death as compared to progression to ESRD. In contrast, the comparative risk of diabetes or hypertension on these outcomes was less clear due to the overall similar effect sizes and the small number of participants reaching ESRD. Our findings suggest that older age, cardiovascular disease, heart failure, and current tobacco use enhance the risk of death, presumably through multiple mechanisms including an increase in cardiovascular events, cancer, and infection, resulting in death prior to progression of renal disease.

The strengths of our study include the methods used to ascertain ESRD, the adjudication of CV death, the long-term follow-up, and the implementation of the competing risk framework for our statistical analysis. In our study, we determined progression to ESRD through linkage to the USRDS and chart review. We detected 17% of our ESRD patients through chart review, underscoring the high degree of under-ascertainment when only relying on the USRDS to identify cases in this population. The use of sources other than the USRDS to identify ESRD may be even more important in older patients, a subgroup that may be more likely to have dialysis withheld or withdrawn.[@CR23] Importantly, we used the CHS adjudicated cause of death, which allowed us, in combination with findings from previous CHS studies, to establish CV death as the leading cause of death in older patients with CKD. In addition, we examined risk factors for ESRD while accounting for the competing risk of death. This statistical approach allowed us to understand risk factors for progression to ESRD as compared to death. Alternative approaches, such as censoring for death or combining ESRD and death as the outcome of interest, would not have allowed us to detect the bi-directional effects of age, BMI, and tobacco use.

Our study had several limitations. One, the findings are primarily applicable to community-dwelling older persons with moderate CKD, and the outcomes may be significantly different in institutionalized older persons. Second, we relied on a single creatinine measurement to estimate the MDRD eGFR, which may have resulted in misclassification of subjects at study entry (with patients most likely being misclassified as having CKD when they did not). However, this type of misclassification would likely result in an underestimate of events as opposed to an overestimate of events (i.e., healthier subjects without CKD would have been inaccurately classified as having CKD and would likely not contribute events but would erroneously be included in the CKD population). In addition, we did not have baseline measures of urinary protein and therefore we could not determine the effect of proteinuria on the risk of renal progression or death. The majority of participants included in our study had stage 3a CKD (78%), and few participants had advanced CKD. Therefore, our study did not include a large number of participants at highest risk for progression to ESRD, and our findings primarily apply to patients with stage 3a CKD. Finally, because only 5% of the cohort progressed to ESRD, our ability to contrast the relative impact of a predictor on the risk of ESRD as compared to death is limited. Nonetheless, our cohort reflects the clinical course of moderate CKD in older community-dwelling persons and does identify important predictors of ESRD as compared with all-cause mortality.

In summary, we found that older patients with moderate CKD are substantially more likely to die than to reach ESRD, and CV death is the single leading cause of death in this population. These findings can aid clinicians in caring for and counseling their older patients with CKD, and highlight the importance of cardiovascular risk reduction and screening for cardiovascular disease in this population.
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